- Author:
I Seul PARK
1
;
Mijeong SON
;
Hyun Woo MA
;
Jihyung KIM
;
Da Hye KIM
;
Seung Won KIM
;
Jae Hee CHEON
Author Information
- Publication Type:Brief Communication
- From:Intestinal Research 2021;19(3):349-353
- CountryRepublic of Korea
- Language:English
- Abstract: The safety and effectiveness of adalimumab was demonstrated in a phase 3 trial in Japanese patients with intestinal Behçet’s disease. The aim of this study was to evaluate the long-term safety and effectiveness of adalimumab in Japanese patients with intestinal Behçet’s disease.